Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the anti-OX40 antibody to significant improvements in symptoms. But, while the trial met its primary endpoints, the biotech still needs to make the case that there is a role for rocatinlimab in a market served by Dupixent.

Headlands Research, a clinical trial site network with locations across the U.S. and Canada, is launching its newest site on the U.S.-Mexico border in El Paso, Texas.

Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive top-line results in systemic lupus erythematosus (SLE) and outlining plans to start a second pivotal trial.

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.